| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/30/2004 | US20040266842 Thiazolyl substituted triazoles as alk5 inhibitors |
| 12/30/2004 | US20040266841 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 12/30/2004 | US20040266839 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors |
| 12/30/2004 | US20040266838 Novel antimicrobial activity of gemfibrozil |
| 12/30/2004 | US20040266836 Salt of acidic AT1-receptor antagonist and basic cardiovascular ingredient; potentiation or synergism; reduction of side effects |
| 12/30/2004 | US20040266835 Inhibitors against complex II of electron transport system |
| 12/30/2004 | US20040266834 Reducing incidence of multidrug resistance; increasing toxicity and efficacy |
| 12/30/2004 | US20040266833 Novel use of certain insulin sensitizers or ppar-gamma agonists |
| 12/30/2004 | US20040266832 Polymorphic forms A and B; providing variable properties for different formulations |
| 12/30/2004 | US20040266831 Modulators of the glucocorticoid receptor and method |
| 12/30/2004 | US20040266830 Insulin sensitivity enhancer and second antidiabetic of different mechanism; suppressing hyperglycemia |
| 12/30/2004 | US20040266828 Gastrointestinal disorders; facilitating healing and decreasing recurrence of ulcers; low dosage, reduced side effects |
| 12/30/2004 | US20040266826 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors |
| 12/30/2004 | US20040266824 Central nervous system disorders, drug abuse, obesity |
| 12/30/2004 | US20040266823 Such as N-[1-(3-phenyl-3-benzoylamino]propyl)-4-piperidinyl]-N-ethylmethanesulfonylphenylacetamide; autoimmune and inflammatory diseases; rheumatoid arthritis; synthesis |
| 12/30/2004 | US20040266822 Secondary amines; tissue specificity; reduced side effects; cardiovascular diseases, diabetes, bronchial and urinary smooth muscle spasms, ischemia, anoxic nerve injury |
| 12/30/2004 | US20040266821 Obesity, diabetes, sexual dysfunction |
| 12/30/2004 | US20040266819 Using a 2-aminoquinoline compound |
| 12/30/2004 | US20040266818 Histone deacetylase inhibitors; antiproliferative agents; autoimmune, allergic and inflammatory diseases; central nervous system disorders; potency, bioavailability |
| 12/30/2004 | US20040266817 3-Substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents |
| 12/30/2004 | US20040266816 Potent and long lasting antimuscarinic agents; respiratory, urological or gastrointestinal disorders |
| 12/30/2004 | US20040266815 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer |
| 12/30/2004 | US20040266814 Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity |
| 12/30/2004 | US20040266813 Injectable sustained-release microspheres of huperzine a compoounds |
| 12/30/2004 | US20040266812 (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione |
| 12/30/2004 | US20040266811 Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue |
| 12/30/2004 | US20040266809 Method of treating multiple myeloma |
| 12/30/2004 | US20040266808 Utilizing N-methyl-D-aspartate (NMDA) receptor antagonist at levels without side effects; uncompetitive open channel blocking |
| 12/30/2004 | US20040266807 Controlled release hydrocodone formulations |
| 12/30/2004 | US20040266806 Autoclaved methylnaltrexone preparation having reduced level of degradation products; storage stability; kits |
| 12/30/2004 | US20040266801 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 12/30/2004 | US20040266800 a selective N-alkylation reaction by adding a base; hydrolysing and amidating; useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors |
| 12/30/2004 | US20040266799 Corticotropin-releasing factor (CRF); such as 4-chloro-2-methyl-5-nitro-8-(2,4-dichloro)phenyl-1,7-naphthyridine for treating stroke, anxiety, depression, and/or irritable bowel syndrome |
| 12/30/2004 | US20040266798 intermediates in the preparation of derivatives which possess anti-cancer activity; synthesis of 4{N-[(6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid |
| 12/30/2004 | US20040266797 Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis |
| 12/30/2004 | US20040266796 Convergent processes for the synthesis of a GARFT inhibitor containing a methyl substituted thiophene core and intermediates therefor |
| 12/30/2004 | US20040266795 reacting a compound of formula I (acetic acid 2-acetoxymethyl-4-(5-amino-7-chloro-imidazo[4,5-b]pyridin-3-yl)-butyl ester) in the presence of a catalyst in a C1-C6 alkyl acetate and ammonium formate |
| 12/30/2004 | US20040266794 transdermal patch to make it easier for young patients ranging from 6 to 18 years old to reduce their calorie intake and thus reduce the health risks associated with being fat |
| 12/30/2004 | US20040266793 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 12/30/2004 | US20040266792 Hydroxyrisperidone compositions and methods |
| 12/30/2004 | US20040266787 Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof |
| 12/30/2004 | US20040266786 1-(2 chlorophenyl-1-piperazinyl)-2-propanol-3-oxy-(2-methoxy-propenyl)-benzene; alpha 2-adrenergic/5-HT2A antagonist, 5-HT re-uptake inhibition, and anti-oxidant activities |
| 12/30/2004 | US20040266785 KMST isoeugenol derivatives and pharmaceutical activity |
| 12/30/2004 | US20040266784 Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| 12/30/2004 | US20040266782 Cyclic amine derivatives-CCR-3 receptor antagonists |
| 12/30/2004 | US20040266780 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 12/30/2004 | US20040266779 Use of c-kit inhibitors for the treatment of myeloma |
| 12/30/2004 | US20040266778 Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| 12/30/2004 | US20040266777 Pyridopyrazines and the use thereof as kinase inhibitors |
| 12/30/2004 | US20040266776 Methods of preventing and reducing the severity of stress-associated conditions |
| 12/30/2004 | US20040266775 for human, veterinary, or phytoprotective use, e.g., inhibiting the cellular sodium-proton antiporter activity, for the treatment of cardiovascular diseases, metabolic diseases, cancerous diseases or fibrotic diseases |
| 12/30/2004 | US20040266774 Amide compounds |
| 12/30/2004 | US20040266773 Such as 4-(3-methoxyphenyl)-5-methyl-6-(2-fluorobenzyl)-2-(N-(2-pyridyl)ethyl-N -methyl)ethyl-pyridazin-3-one; drugs/prodrugs for treatment of sex-hormone related conditions in men/women |
| 12/30/2004 | US20040266772 Polymorph salt of a pryridazinone derivative for the treatment of arrythmia |
| 12/30/2004 | US20040266771 Use of tyrosine kinase inhibitors for treating bone loss |
| 12/30/2004 | US20040266770 treating diseases that are triggered by persistent angiogenesis; inhibition of the VEGF receptor |
| 12/30/2004 | US20040266769 Antiinflammatory agents; inflammatory bowel disorders; capable of complexing with a deacetylase catalytic site and/or a metal ion |
| 12/30/2004 | US20040266766 Selective urokinase inhibitors |
| 12/30/2004 | US20040266765 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 12/30/2004 | US20040266764 Hydroxamic acid derivatives |
| 12/30/2004 | US20040266761 thromboembolic disorder treatment; anticoagulant agents |
| 12/30/2004 | US20040266759 Possess antithrombotic and anticoagulant properties; example compound: 1-(5-Chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine |
| 12/30/2004 | US20040266757 4-(Oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 12/30/2004 | US20040266756 Antifungal 4-substituted 5,6-dihydro-4h-pyrrolo[1,2-a][1,4] benzodiazepines |
| 12/30/2004 | US20040266755 Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| 12/30/2004 | US20040266753 Benzo[a]pyrano[3,2-h]acridin-7-one compounds |
| 12/30/2004 | US20040266750 Beta-lactamyl vasopressin v1aantagonists |
| 12/30/2004 | US20040266749 Methods for cystic fibrosis disease assessment and methods for treating anaerobic P. aeruginosa biofilms in cystic fibrosis disease |
| 12/30/2004 | US20040266747 Long chain fatty alcohol substituents in antineoplastic agents |
| 12/30/2004 | US20040266746 the sensitivity of cells typical of various proliferative disorders to the ansamycin CNF-101 ("17-AAG") is proportional to the HER-2 levels in those cells |
| 12/30/2004 | US20040266745 Estrogen-gestagen combination preparations and uses thereof |
| 12/30/2004 | US20040266744 useful as intermediates in the preparation of steroids having medicinal properties |
| 12/30/2004 | US20040266743 more than about 20% by weight of the aldosterone receptor antagonist is released at about four hours after initiation of the test |
| 12/30/2004 | US20040266742 Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| 12/30/2004 | US20040266739 Composition comprising minocycline as an effective component for prevention and treatment of dementia, and learning and memory impairments |
| 12/30/2004 | US20040266737 Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders |
| 12/30/2004 | US20040266734 administering encapsulated bisphosphonate or gallium which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following myocardium necrosis; cardiovascular disorders |
| 12/30/2004 | US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1) |
| 12/30/2004 | US20040266732 Therapeutic agents, methods, and treatments |
| 12/30/2004 | US20040266727 Nutritional supplement having a unique soluble and insoluble fiber blend and method of making the same |
| 12/30/2004 | US20040266726 yeast-derived ingredient having beta 1,3/1.6 glucan structure (IMMUTOL) or Norwegian Beta Glucan (TM); natural killer cell activating capabilities and tumor angiogenesis inhibiting capability by oral administration |
| 12/30/2004 | US20040266725 Polysaccharide-containing compositions and use thereof |
| 12/30/2004 | US20040266724 Vitamin B12 and folic acid for elevated serum metabolite levels of homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2- methylcitric acid (2-MCA) |
| 12/30/2004 | US20040266723 Antiviral agents for treatment of Flaviviridae infections |
| 12/30/2004 | US20040266722 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| 12/30/2004 | US20040266720 Splice-region antisense composition and method |
| 12/30/2004 | US20040266719 immunostimulatory CpG oligonucleotide for inducing a mucosal immune response for treating a subject having an infection comprising enterovirus, calciviridae, vesicular stomatitis, rotavirus infection, Salmonella spp. infection, Helicobacter pyloris infection and M. intracellulare infection |
| 12/30/2004 | US20040266717 Administering polynucleotide capable of modulating an electrical property in a standard cardiac electrophysiological assay; expressing the polynucleotide in the mammal to prevent or treat the cardiac arrhythmia |
| 12/30/2004 | US20040266716 Administering polynucleotide capable of modulating an electrical property in a standard cardiac electrophysiological assay; expressing the polynucleotide in the mammal to prevent or treat the cardiac arrhythmia |
| 12/30/2004 | US20040266715 Neurite regeneration |
| 12/30/2004 | US20040266710 Immunotherapy; induce immunology response |
| 12/30/2004 | US20040266709 Immunotherapy; induction immunology response |
| 12/30/2004 | US20040266704 Therapy for drug resistant cancer |
| 12/30/2004 | US20040266702 Topical treatment or prevention of ocular infections |
| 12/30/2004 | US20040266701 Novel polyol macrolide antitumor-antibiotics from the novel actinomycete strain CNQ140 |
| 12/30/2004 | US20040266687 Antiproliferative agents; antiinflammatory agents; angiogenesis inhibitors; anticancer agents |
| 12/30/2004 | US20040266683 Prevention and treatment of cardiac arrhythmias |
| 12/30/2004 | US20040266682 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits |
| 12/30/2004 | US20040266678 Methods and compositions for treating polycystic ovary syndrome |
| 12/30/2004 | US20040266676 Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid |